|
|||||
Boston Scientific Announces Launch of New Balloon Catheters |
|||||
|
|||||
NATICK, Mass., Dec. 2 -- Boston Scientific Corporation announced today the launch of two new balloon catheters in the United States, the Maverick2 Monorail Coronary Balloon Dilatation Catheter and the Quantum Maverick® Coronary Balloon Dilatation Catheter. Both have been approved by the U.S. Food and Drug Administration and have already been launched in international markets. "The addition of these two products further strengthens Boston Scientific's leadership in balloon catheter technology worldwide," said Paul LaViolette, Boston Scientific Senior Vice President and Group President, Cardiovascular. "They are well-suited for challenging situations and will provide clinicians options for a wide range of applications." Maverick2 Monorail Coronary Balloon Dilatation Catheter "The Maverick2 Monorail balloon catheter is a great treatment option for challenging clinical cases," said Antonio Colombo, M.D. EMO Centro Cuore Columbus, Milan. "The catheter's lower profile shaft, pushability and durability is designed to allow physicians to treat lesions of great complexity." The Maverick2 balloon catheter features the TrakTip, which is attached via laser bonding to create a flexible, kink-resistant taper. The TrakTip's small lesion entry profile is also designed to enable excellent crossability and easy lesion engagement. Quantum Maverick Coronary Balloon Dilatation Catheter "We are finding in our lab that the Quantum Maverick balloon catheter delivers the necessary dilatation force to properly post-dilate a stent or resistant lesion," said Peter Ver Lee, M.D., Director, Cardiac Catheterization Lab, Eastern Maine Medical Center in Bangor. "It delivered beautifully in tortuous and difficult-to-reach anatomy." The Quantum Maverick balloon catheter is available in both Monorail® and Over-The-Wire versions and replaces the Company's Quantum Ranger and Quantum Monorail balloon catheters. Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with the regulatory approval process, commercialization of new technologies, competitive offerings, intellectual property and other factors described in the Company's filings with the Securities and Exchange Commission.
|